• 2017

Company Description

We enable a new standard of antibiotic administration for infection disease, shortening the susceptibility testing cycle by 70-90%.

We are developing a novel technology aiming to reduce the burden of infection disease by enabling a new standard in antibiotic administration. Our product is a rapid, precise, and cost-effective antibiotics susceptibility analysis system, eliminating the need for Petri dish-based testing in Clinical Laboratory. BactoSense introduces a unique mechanism of action providing the shortest Total Time to Result (TTTR) of 2-8 hours as an alternative to the current Golden standard of 3-5 days. The outcomes are decreased mortality rates, hospital and intensive care unit LOS (Length of Stay) and major cost avoidance.